Akorn Stock Price, Forecast & Analysis (NASDAQ:AKRX)

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Akorn, Inc. (NASDAQ:AKRX) announced its earnings results on Thursday, October, 31st. The company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.06. The business had revenue of $176.24 million for the quarter, compared to analysts' expectations of $176.15 million. Akorn had a negative net margin of 53.62% and a negative return on equity of 19.95%. The company's quarterly revenue was up 6.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.06) EPS. View Akorn's Earnings History.

4 brokers have issued twelve-month target prices for Akorn's stock. Their forecasts range from $4.00 to $11.00. On average, they anticipate Akorn's stock price to reach $7.00 in the next year. This suggests a possible upside of 71.1% from the stock's current price. View Analyst Price Targets for Akorn.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akorn.

News coverage about AKRX stock has trended very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Akorn earned a news sentiment score of -3.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Akorn.

Akorn saw a decline in short interest during the month of October. As of October 31st, there was short interest totalling 7,650,000 shares, a decline of 17.6% from the September 30th total of 9,280,000 shares. Based on an average trading volume of 1,860,000 shares, the days-to-cover ratio is currently 4.1 days. Approximately 8.1% of the shares of the company are short sold. View Akorn's Current Options Chain.

Some companies that are related to Akorn include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Akorn's stock is owned by a number of of institutional and retail investors. Top institutional investors include Mackay Shields LLC (0.57%), Gabelli Funds LLC (0.35%), Gamco Investors INC. ET AL (0.29%), Rhumbline Advisers (0.23%), Assenagon Asset Management S.A. (0.18%) and California Public Employees Retirement System (0.11%). Company insiders that own Akorn stock include Alan D Weinstein, Brian Tambi, John N Kapoor, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.

AKRX stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., SG Americas Securities LLC, Chicago Equity Partners LLC and Gabelli Funds LLC. View Insider Buying and Selling for Akorn.

AKRX stock was acquired by a variety of institutional investors in the last quarter, including Mackay Shields LLC, Tibra Equities Europe Ltd, State of Alaska Department of Revenue, Nisa Investment Advisors LLC, Gamco Investors INC. ET AL, California Public Employees Retirement System, Rhumbline Advisers and Moors & Cabot Inc.. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKRX stock can currently be purchased for approximately $4.09.

Akorn has a market capitalization of $515.95 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.

The official website for Akorn is http://www.akorn.com/.

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]